One day diagnostic will advance and NASH-treatment (and probably initial diagnosis) will be followed without biopsy, but that is not current case for ICPT. Pumpers are promoting ICPT as GILD acquisition target (160-250?). Current NRx# point 300-degree opposite.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.